Insmed
Clinical trials sponsored by Insmed, explained in plain language.
Insmed
INSM
NASDAQ
A biopharmaceutical company focused on serious rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaled powder shows promise for Long-Term PAH control Results expected Dec 2026 (estimated) May already have reported ↗
- Liver health may change how body handles inhaled lung drug Results expected Feb 2027 (estimated) May already have reported ↗
- Could a new oral drug pass its first safety hurdle? Results expected Mar 2027 (estimated)